Perfomance in Delivering (Commercial Trials)

REC Ref	IRAS ID	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
17/YH/0387	230570	A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients wi	Number Agreed	3	3	Date Agreed	31/07/2019	2	31/07/2018	2	Recruitment Finished	Sponsor suspended recruitment and closed the open label pembrolizumab + epacadostat arm. As a result we were unable to reach our target.
17/YH/0388	104119	A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults with stable coronary artery disease	Range Agreed	2	13	Date Agreed	30/09/2018	4	31/07/2018	4	Recruitment Finished	
16/LO/2153	217054	A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (AFFIRM-AHF)	Range Agreed	2	10	Date Agreed	30/06/2018	3	01/09/2018	3	Recruitment Finished	

17/EE/0038	217456	A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF-a I	Number Agreed	3	3	Date Agreed	31/05/2019	0	30/08/2018	0	Recruitment Finished	1 patient screen failed and study closed early to recruitment due to not being feasible.
17/LO/2052	232092	A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS	Range Agreed	2	6	Date Agreed	26/09/2018	0	31/08/2018	0	Recruitment Finished	3 patients screen failed and study closed to recruitment due to study target being met.
17/LO/0441	222471	A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer	Number Agreed	4	4	Date Agreed	05/03/2018	1	09/07/2018	1	Recruitment Finished	1 patient recruited and 1 patient screen failed. Recruitment was more difficult than expected.
18/NW/0173	242176	"Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes"	Number Agreed	8	8	Date Agreed	19/11/2018	9	01/11/2018	9	Recruitment Finished	

16/EM/0193	190690	A Phase III, double-blind, randomized placebo-controlled study to evaluate the effectsof dalcetrapib on cardiovascular (CV) Risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial	Number Agreed	6	6	Date Agreed	30/11/2018	8	21/12/2018	8	Recruitment Finished	
17/YH/0182	227570	A Phase 1/2, open-label, multicentre, dose escalation and dose expansion study of NKTR-214 and Nivolumab in patients with select locally advanced or metastatic solid tumor malignancies	Number Agreed	5	5	Date Agreed	31/07/2018	1	02/11/2018	1	Withdrawn By Sponsor	Sponsor (NEKTAR) decided to close our site for the PIVOT-02 study. There were 4 cohorts open and 3 of them closed before we could recruit. With regards to the last cohort left open, we didn't have any suitable patients for it.
17/LO/0085	216434	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE – CONVERSION)	Number Agreed	4	4	Date Agreed	31/01/2018	3	31/12/2018	3	Recruitment Finished	Sponsor met their global recruitment target and closed us as a site, therefore we did not meet our recruitment target.
16/SC/0387	202827	Assessment of the effect of Positive Airway Pressure on energy and vitality in mild Obstructive Sleep Apnea patients.	Number Agreed	20	20	Date Agreed	31/01/2018	45	31/01/2019	45	Recruitment Finished	

17/LO/1068	224973	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC	Number Agreed	4	4	Date Agreed	30/11/2018	9	09/01/2019	9	Recruitment Finished	
16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction	Number Agreed	3	3	Date Agreed	01/05/2018	3	25/01/2019	3	Recruitment Finished	
14/LO/1672	158949	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	Number Agreed	1	1	Date Agreed	30/09/2017	1	27/09/2018	1	Recruitment Finished	
18/LO/0116	239646	A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer	Number Agreed	5	5	Date Agreed	30/11/2018	4	13/02/2019	4	Recruitment Finished	Study enrollment finished prior to the study team being able to meet their recruitment target.

17/NW/0162	220300	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	Range Agreed	1	2	Date Agreed	31/10/2019	2	13/03/2019	2	Recruitment Finished	
16/LO/0043	194345	A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma.	Number Agreed	3	3	Date Agreed	30/09/2018	4	04/02/2019	7	Recruitment Finished	
17/SC/0253	226685	MonarchE: Protocol I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone R	Number Agreed	4	4	Date Agreed	30/06/2019	4	15/02/2019	4	Recruitment Finished	
17/EM/0005	215706	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv mecarbil on Mortality and Morbidity in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF)	Range Agreed	2	8	Date Agreed	03/01/2019	2	05/06/2019	2	Recruitment Finished	

18/NE/0223	249460	A prospective, single arm, multi-center, open-label, non-randomized trial to further evaluate the safety of 1 month (as short as 28 days) DAPT in HBR subjects undergoing PCI with XIENCE	Range Agreed	0	10	Date Agreed	31/08/2020	0	22/04/2019	0	Recruitment Finished	
18/EM/0003	234521	A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously	Number Agreed	2	2	Date Agreed	31/03/2019	0	11/06/2019	0	Withdrawn By Host	The site experienced difficulty in finding any eligible patients to be recruited to the study, therefore decided to close.